1st approved Symbicort generic, Breyna, now available in US
Aug 7, 2023 · The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available to eligible patients.. Like Symbicort, Breyna is approved as a maintenance therapy to lower airflow obstruction and prevent exacerbations in people with COPD, and for asthma patients, ages 6 and older.
Low-dose Morphine Improves Health in COPD Patients With …
Sep 3, 2020 · by Steve Bryson, PhD September 3, 2020. Regular, low-dose oral morphine led to significant health improvements in adults with advanced chronic obstructive pulmonary disease (COPD) who regularly experienced shortness of breath, according to results of a Phase 4 clinical trial. Treatment with morphine did not cause lung-related side effects, and ...
LupinHaler, generic version of Spiriva HandiHaler ...
Aug 28, 2023 · In Europe, generics of Boehringer Ingelheim’s Spiriva HandiHaler began launching in 2021, including ones from Glenmark Pharmaceuticals and Phargentis, but these medications haven’t become available in the U.S.. COPD is a chronic lung disease wherein the airways become blocked, leading to progressively worsening disease symptoms that include shortness of breath and wheezing.
COPD Trial Shows Breztri Aerosphere Significantly Reduces...
by Joana Carvalho, PhD June 30, 2020. Breztri Aerosphere, AstraZeneca ’s triple combination therapy for chronic obstructive pulmonary disease (COPD), significantly reduces the frequency of moderate or severe exacerbations, compared to dual combination therapies, in patients with moderate to very severe forms of the disease, a Phase 3 trial shows.
Generic of COPD, Asthma Drug Symbicort Given FDA Approval
Mar 17, 2022 · FDA Approves Generic Version of Symbicort for COPD, Asthma. by Patricia Inácio, PhD March 17, 2022. The U.S. Food and Drug Administration (FDA) has approved the first generic equivalent to AstraZeneca ’s Symbicort (budesonide and formoterol fumarate dihydrate) as a maintenance treatment for chronic obstructive pulmonary disease (COPD).
Ensifentrine, now Ohtuvayre, wins FDA approval for COPD
Jun 27, 2024 · The U.S. Food and Drug Administration (FDA) has approved Verona Pharma ’s ensifentrine as an inhaled maintenance therapy for adults with chronic obstructive pulmonary disease (COPD). The decision makes ensifentrine — to be marketed under the brand name Ohtuvayre — the first therapy with a new mechanism of action to win approval for COPD ...
Dupixent approved in US for adults with poorly controlled COPD
Sep 30, 2024 · by Margarida Maia, PhD September 30, 2024. The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with poorly controlled chronic obstructive pulmonary disease (COPD) and high counts of immune cells called eosinophils. Elevated eosinophils are a marker of type 2 inflammation ...
Low climate-impact inhalers as effective as pressurized ones: Study
by Steve Bryson, PhD October 7, 2024. Dry-powder corticosteroid inhalers, or those designed to have a low impact on climate, are as effective as those based on pressurized, metered doses at reducing the risk of poor outcomes in people with both chronic obstructive pulmonary disease (COPD) and asthma. A large study in Denmark found the two ...
COPD News Today Home | COPD News Today
The U.S. Food and Drug Administration (FDA) has approved Abrysvo, a vaccine that protects against lung infections caused by the respiratory syncytial virus — commonly known as RSV — for adults as young as 18 with chronic obstructive pulmonary disease (COPD) or other conditions that increase the risk of…. October 21, 2024 News by Margarida ...
FDA to decide on Dupixent for COPD inflammation by end of June
Feb 26, 2024 · A decision is expected by June 27, according to a joint press release. Dupixent received breakthrough therapy status from the FDA as an add-on for people with uncontrolled COPD and type 2 inflammation. The designation is meant to accelerate a therapy’s clinical development and regulatory review. If it’s approved, Dupixent would become the ...